Quarterly Performance

‍

Palantir {{ m-tag option="price" ticker="PLTR" currency="USD" }} reported second-quarter revenue of $678.13 million, marking a 27% year-over-year increase and surpassing analysts' estimates compiled by Visible Alpha. Net income reached $134 million, with earnings per share hitting a record high of 6 cents.

‍

Commercial Growth

‍

The company's commercial revenue surged by 33% to $307 million. Notably, U.S. commercial sales skyrocketed by 55% to $159 million, highlighting significant traction in the domestic market. CEO Alex Karp emphasized the steady re-acceleration of the business and the unprecedented opportunities ahead.

Palantir's government revenue also grew substantially, rising 23% to $371 million and surpassing the $349 million estimates. This performance underscores Palantir's strong foothold in the government sector, which continues to be a significant revenue stream.

‍

Future Outlook

‍

Palantir anticipates third-quarter revenue to be between $697 million and $701 million, exceeding analysts' expectations. The company also raised its full-year guidance to a range of $2.74 billion to $2.75 billion, up from the previous forecast of $2.68 billion to $2.69 billion.

‍

Stock Performance

‍

Following the earnings announcement, Palantir's stock surged nearly 15% to $27.68 in extended trading. The stock continued its upward momentum in after-hours trading, reflecting strong investor sentiment and confidence in the company's prospects.

Palantir Technologies reported an exceptional second quarter, with revenue up 27% to $678 million and earnings per share reaching 6 cents. The stock soared 15% on these results, driven by strong commercial and government sales.

‍

‍
The information on mexem.com is for general informational purposes only. It should not be regarded as investment advice. Investing in stocks involves risk. A stock's past performance is not a reliable indicator of its future performance. Always consult a financial advisor or trusted sources before making any investment decisions.
‍

‍